BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 14708711)

  • 1. HLA-G modulates immune responses by diverse receptor interactions.
    Hofmeister V; Weiss EH
    Semin Cancer Biol; 2003 Oct; 13(5):317-23. PubMed ID: 14708711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
    LeMaoult J; Zafaranloo K; Le Danff C; Carosella ED
    FASEB J; 2005 Apr; 19(6):662-4. PubMed ID: 15670976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.
    Shiroishi M; Tsumoto K; Amano K; Shirakihara Y; Colonna M; Braud VM; Allan DS; Makadzange A; Rowland-Jones S; Willcox B; Jones EY; van der Merwe PA; Kumagai I; Maenaka K
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8856-61. PubMed ID: 12853576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells.
    Navarro F; Llano M; Bellón T; Colonna M; Geraghty DE; López-Botet M
    Eur J Immunol; 1999 Jan; 29(1):277-83. PubMed ID: 9933109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
    Morel E; Bellón T
    J Immunol; 2008 Aug; 181(4):2368-81. PubMed ID: 18684926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.
    Riteau B; Menier C; Khalil-Daher I; Martinozzi S; Pla M; Dausset J; Carosella ED; Rouas-Freiss N
    Int Immunol; 2001 Feb; 13(2):193-201. PubMed ID: 11157852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
    Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
    Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E.
    Valés-Gómez M; Reyburn HT; Erskine RA; López-Botet M; Strominger JL
    EMBO J; 1999 Aug; 18(15):4250-60. PubMed ID: 10428963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrameric complexes of HLA-E, HLA-F, and HLA-G.
    Allan DS; Lepin EJ; Braud VM; O'Callaghan CA; McMichael AJ
    J Immunol Methods; 2002 Oct; 268(1):43-50. PubMed ID: 12213342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.
    Rajagopalan S; Long EO
    J Exp Med; 1999 Apr; 189(7):1093-100. PubMed ID: 10190900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells.
    Allan DS; Colonna M; Lanier LL; Churakova TD; Abrams JS; Ellis SA; McMichael AJ; Braud VM
    J Exp Med; 1999 Apr; 189(7):1149-56. PubMed ID: 10190906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
    King A; Allan DS; Bowen M; Powis SJ; Joseph S; Verma S; Hiby SE; McMichael AJ; Loke YW; Braud VM
    Eur J Immunol; 2000 Jun; 30(6):1623-31. PubMed ID: 10898498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2.
    Miller JD; Weber DA; Ibegbu C; Pohl J; Altman JD; Jensen PE
    J Immunol; 2003 Aug; 171(3):1369-75. PubMed ID: 12874227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell activation and inhibition by receptors for MHC class I.
    López-Botet M; Bellón T
    Curr Opin Immunol; 1999 Jun; 11(3):301-7. PubMed ID: 10375552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex.
    Pende D; Sivori S; Accame L; Pareti L; Falco M; Geraghty D; Le Bouteiller P; Moretta L; Moretta A
    Eur J Immunol; 1997 Aug; 27(8):1875-80. PubMed ID: 9295021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutting edge: HLA-E binds a peptide derived from the ATP-binding cassette transporter multidrug resistance-associated protein 7 and inhibits NK cell-mediated lysis.
    Wooden SL; Kalb SR; Cotter RJ; Soloski MJ
    J Immunol; 2005 Aug; 175(3):1383-7. PubMed ID: 16034073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production.
    Mingari MC; Vitale C; Cambiaggi A; Schiavetti F; Melioli G; Ferrini S; Poggi A
    Int Immunol; 1995 Apr; 7(4):697-703. PubMed ID: 7547697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells.
    Brooks AG; Borrego F; Posch PE; Patamawenu A; Scorzelli CJ; Ulbrecht M; Weiss EH; Coligan JE
    J Immunol; 1999 Jan; 162(1):305-13. PubMed ID: 9886400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis.
    Borrego F; Ulbrecht M; Weiss EH; Coligan JE; Brooks AG
    J Exp Med; 1998 Mar; 187(5):813-8. PubMed ID: 9480992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
    Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
    Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.